Pharmaceutical Benefits Scheme (PBS) - Changes to PBS listings for Opdualag^® and Vyxeos^®

Page last updated: 1 December 2024

As of 1 December 2024, combination chemotherapy medicines, Opdualag and Vyxeos, will be transitioned from the Highly Specialised Drugs Program to the Efficient Funding of Chemotherapy Program, consistent with recommendations by the Pharmaceutical Benefits Advisory Committee.